Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QXL138AM in Advanced Solid Tumors and Multiple Myeloma
NCT06582017Phase 1Recruiting
- Sponsor
- Nammi Therapeutics
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of QXL138AM in solid tumor, multiple myeloma (MM), ovarian cancer and 8 more (4 arms), sponsored by Nammi Therapeutics. Primary endpoint: Incidence of Adverse Events at 3.5 years. Started Aug 2024; status: recruiting.
02
Drugs
QXL138AM
03
Conditions
solid tumormultiple myeloma (MM)ovarian cancerpancreatic cancer (PC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06582017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06582017.